CHIARINI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.459
NA - Nord America 5.067
EU - Europa 2.121
SA - Sud America 757
AF - Africa 74
Continente sconosciuto - Info sul continente non disponibili 39
OC - Oceania 5
Totale 13.522
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.919
CN - Cina 1.937
SG - Singapore 1.757
IT - Italia 582
BR - Brasile 581
HK - Hong Kong 506
VN - Vietnam 390
GB - Regno Unito 366
KR - Corea 328
FI - Finlandia 252
SE - Svezia 189
BD - Bangladesh 169
RU - Federazione Russa 166
DE - Germania 137
FR - Francia 129
ID - Indonesia 82
AR - Argentina 68
CA - Canada 65
IN - India 63
NL - Olanda 63
LT - Lituania 56
MX - Messico 45
IQ - Iraq 35
IE - Irlanda 34
EC - Ecuador 33
JP - Giappone 29
TR - Turchia 26
AT - Austria 24
UA - Ucraina 23
ZA - Sudafrica 21
PL - Polonia 19
PK - Pakistan 17
AE - Emirati Arabi Uniti 16
PY - Paraguay 14
VE - Venezuela 14
CO - Colombia 13
ES - Italia 13
CL - Cile 12
KE - Kenya 12
CZ - Repubblica Ceca 10
UZ - Uzbekistan 10
CR - Costa Rica 9
IL - Israele 9
MA - Marocco 9
PE - Perù 9
SA - Arabia Saudita 9
NP - Nepal 8
TH - Thailandia 8
MY - Malesia 7
TN - Tunisia 7
UY - Uruguay 7
BO - Bolivia 6
GT - Guatemala 6
OM - Oman 6
PT - Portogallo 6
AL - Albania 5
BG - Bulgaria 5
CG - Congo 5
DO - Repubblica Dominicana 5
HR - Croazia 5
PA - Panama 5
PH - Filippine 5
RO - Romania 5
AU - Australia 4
DZ - Algeria 4
EG - Egitto 4
JM - Giamaica 4
LK - Sri Lanka 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LV - Lettonia 3
MD - Moldavia 3
RS - Serbia 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
TW - Taiwan 3
AM - Armenia 2
BE - Belgio 2
BH - Bahrain 2
BY - Bielorussia 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
IR - Iran 2
JO - Giordania 2
KZ - Kazakistan 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
PR - Porto Rico 2
QA - Qatar 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BN - Brunei Darussalam 1
Totale 13.469
Salva come PNG Salva come JPEG
Città #
Hefei 1.197
Santa Clara 1.096
Singapore 934
Ashburn 779
San Jose 604
Hong Kong 500
Seoul 328
Dallas 300
Council Bluffs 230
Helsinki 229
London 216
The Dalles 155
Beijing 147
Nyköping 140
Los Angeles 128
Ho Chi Minh City 118
Hanoi 108
Chicago 100
Milan 90
Lauterbourg 75
Shanghai 74
Kent 70
Jakarta 64
Buffalo 61
Munich 58
Fairfield 54
Moscow 53
New York 51
Chandler 50
Houston 45
São Paulo 45
Boardman 43
Bologna 37
Dublin 33
Woodbridge 32
Southend 30
Parma 29
Amsterdam 28
Frankfurt am Main 28
Modena 27
Rome 25
Tampa 25
Porto Alegre 24
Redondo Beach 24
Salt Lake City 24
Cambridge 23
Nuremberg 21
Atlanta 20
Tokyo 20
Columbus 18
Guangzhou 18
Rio de Janeiro 18
San Anselmo 18
Seattle 18
Wilmington 18
Orem 17
Brasília 16
Reggio Emilia 16
Baghdad 15
Haiphong 15
Indianapolis 15
Mexico City 15
Miano 15
North Bergen 15
Washington 15
Chennai 14
Da Nang 14
Phoenix 14
Warsaw 13
Montreal 12
Stockholm 12
Toronto 12
Belo Horizonte 11
Brooklyn 11
Kilburn 11
Lancaster 11
Lappeenranta 11
Nairobi 11
Paris 11
Quito 11
Turku 11
Elk Grove Village 10
Naples 10
Tashkent 10
Vancouver 10
Vienna 10
Boston 9
Chiswick 9
Curitiba 9
Dhaka 9
Erbil 9
Padova 9
Poplar 9
San Diego 9
Tianjin 9
Turin 9
Ann Arbor 8
Assago 8
Brescia 8
Campinas 8
Totale 9.216
Salva come PNG Salva come JPEG
Nome #
Dual inhibition of PI3K/mTOR signaling in chemoresistant AMLprimary cells. 319
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 280
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 270
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer 261
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning offthe prosurvival ER chaperone BIP/Grp78 and turning on the proapoptotic NF-κB 220
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 194
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 187
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK) 186
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 179
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 178
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 177
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia 175
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 173
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 170
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 169
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies 168
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 163
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 162
Surface Charge Overrides Protein Corona Formation in Determining the Cytotoxicity, Cellular Uptake, and Biodistribution of Silver Nanoparticles 160
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics 160
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 160
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 159
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model 159
The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia 155
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 155
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a 154
Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells 152
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications 152
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells 152
At the Nucleus of Cancer – How the Nuclear Envelope Controls Tumor Progression 149
13. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation 147
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 145
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 144
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 143
Current treatment strategies for inhibiting mTOR in cancer 143
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS 143
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 143
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells 141
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 141
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies 141
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression 141
Magnesium and strontium-enriched bioactive glasses: superior biocompatibility and angiogenesis, beyond the gold standard 140
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside 139
Therapeutic targeting of CK2 in acute and chronic leukemias 139
GSK-3: a multifaceted player in acute leukemias 139
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 138
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines 137
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia 137
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 137
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 136
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia 135
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment 132
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels 131
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 130
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications 130
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 129
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 127
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia 127
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 126
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response 123
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance 121
Differential Cytotoxicity of Surface-Functionalized Silver Nanoparticles in Colorectal Cancer and Ex-Vivo Healthy Colonocyte Models 121
K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway 118
Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL) 118
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms 117
The unfolded protein response: a novel therapeutic target in acute leukemias 117
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 115
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia 114
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia 113
Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells 113
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 112
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 112
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia 111
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 110
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 110
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML 109
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 106
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update 105
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology 105
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 104
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 103
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 103
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 103
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 100
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 98
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib 95
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 94
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias 94
C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes 90
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 90
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 89
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy 89
C025 Role of lipid signaling pathways in the response to erythropoietin in low risk MDS patients 88
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 86
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 86
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis 83
Development and 3D Printing of AESO-Based Composites Containing Olive Pit Powder 62
The Association Between Muscle Strength, Body Cell Mass, and Training Session Hours in Young Female Artistic Gymnasts: A Pilot Study 55
New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways 55
Advances in Targeting Signal Transduction Pathways 6
Totale 13.522
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.588
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202271 0 6 4 13 2 4 2 6 6 7 13 8
2022/2023514 5 7 11 24 41 66 30 61 94 19 58 98
2023/2024871 35 26 37 145 120 64 173 60 20 28 86 77
2024/20253.810 83 19 13 227 848 625 109 143 385 125 608 625
2025/20267.687 707 634 1.099 876 661 387 864 280 638 654 389 498
2026/2027287 243 44 0 0 0 0 0 0 0 0 0 0
Totale 13.522